- Home
- RITR vs LXEO Comparison
RITR vs LXEO Comparison
Compare RITR & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- LXEO
- Stock Information
- Founded
- RITR 2015
- LXEO 2017
- Country
- RITR Hong Kong
- LXEO United States
- Employees
- RITR N/A
- LXEO N/A
- Industry
- RITR
- LXEO
- Sector
- RITR
- LXEO
- Exchange
- RITR NYSE
- LXEO Nasdaq
- Market Cap
- RITR 276.0M
- LXEO 286.3M
- IPO Year
- RITR 2024
- LXEO 2023
- Fundamental
- Price
- RITR $7.25
- LXEO $10.16
- Analyst Decision
- RITR
- LXEO Strong Buy
- Analyst Count
- RITR 0
- LXEO 7
- Target Price
- RITR N/A
- LXEO $22.14
- AVG Volume (30 Days)
- RITR 172.1K
- LXEO 328.9K
- Earning Date
- RITR 11-03-2024
- LXEO 11-21-2024
- Dividend Yield
- RITR N/A
- LXEO N/A
- EPS Growth
- RITR N/A
- LXEO N/A
- EPS
- RITR 0.04
- LXEO N/A
- Revenue
- RITR $32,198,033.00
- LXEO N/A
- Revenue This Year
- RITR N/A
- LXEO N/A
- Revenue Next Year
- RITR N/A
- LXEO N/A
- P/E Ratio
- RITR $176.56
- LXEO N/A
- Revenue Growth
- RITR 74.80
- LXEO N/A
- 52 Week Low
- RITR $3.30
- LXEO $7.86
- 52 Week High
- RITR $8.38
- LXEO $22.33
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- LXEO 53.81
- Support Level
- RITR N/A
- LXEO $7.88
- Resistance Level
- RITR N/A
- LXEO $11.30
- Average True Range (ATR)
- RITR 0.00
- LXEO 0.72
- MACD
- RITR 0.00
- LXEO 0.31
- Stochastic Oscillator
- RITR 0.00
- LXEO 61.41
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.